Potential role of histamine releasing factor (HRF) as a therapeutic target for treating asthma and allergy

Journal of Asthma and Allergy

Volumn , Issue 5, 2012, Pages 51-59

  MacDonald, Susan M ^a  

^a JOHNS HOPKINS ASTHMA AND ALLERGY CENTER   (United States)

Author keywords

Human basophils; Human eosinophils; Inducible transgenic mouse; Interleukin 13; Interleukin 4; Translationally controlled tumor protein (TCTP)

Indexed keywords

DOXYCYCLINE; HISTAMINE DERIVATIVE; HISTAMINE RELEASING AGENT; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; INOSITOL 1 PHOSPHATASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TETRACYCLINE; TRANSLATIONALLY CONTROLLED TUMOR PROTEIN; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ALLERGY; ASTHMA; B LYMPHOCYTE; BASOPHIL; CELL ACTIVATION; CELL POPULATION; DISEASE EXACERBATION; DRUG TARGETING; ENZYME ACTIVITY; EOSINOPHIL; HUMAN; INTRACELLULAR SIGNALING; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; REVIEW; T LYMPHOCYTE;

EID: 84874785758     PISSN: 11786965     EISSN: None     Source Type: Journal    
DOI: 10.2147/JAA.S28868     Document Type: Review

References (80)

1. Yenofsky R, Cereghini S, Krowczynska A, Brawerman G. Regulation of mRNA utilization in mouse erythroleukemia cells induced to differentiate by exposure to dimethyl sulfoxide. Mol Cell Biol. 1983;3(7): 1197-1203.
2. Chitpatima ST, Makrides S, Bandyopadhyay R, Brawerman G. Nucleotide sequence of a major messenger RNA for a 21 kilodalton polypeptide that is under translational control in mouse tumor cells. Nucleic Acids Res. 1988;16(5):2350.
3. MacDonald SM, Lichtenstein LM, Proud D, Plaut M, Naclerio RM, Kagey-Sobotka A. Studies of IgE-dependent histamine releasing factors: Heterogeneity of IgE. J Immunol. 1987;139(2):506-512.
4. MacDonald SM, Rafnar T, Langdon J, Lichtenstein LM. Molecular identification of an IgE-dependent histamine releasing factor. Science. 1995;269(5224):688-690.
5. MacDonald SM, Bhisutthibhan J, Shapiro TA, etal. Immune mimicry in malaria: Plasmodium falciparum secretes a functional histamine-releasing factor homolog in vitro and in vivo. Proc Natl Acad Sci U S A. 2001;98(19):10829-10832.
6. Gnanasekar M, Rao KV, Chen L, etal. Molecular characterization of a calcium binding translationally controlled tumor protein homologue from the filarial parasites Brugia malayi and Wuchereria bancrofti. Mol Biochem Parasitol. 2002;121(1):107-118.
7. Rao KV, Chen L, Gnanasekar M, Ramaswamy K. Cloning and characterization of a calcium-binding histamine-releasing protein from Schistosoma mansoni. J Biol Chem. 2002;277(34):31207-31213.
8. Langdon JM, Vonakis BM, MacDonald SM. Identification of the interaction between the human recombinant histamine releasing factor/translationally controlled tumor protein and elongation factor-1 delta (also known as eElongation factor-1B beta). Biochem Biophys Acta. 2004;1688(3):232-236.
9. Cans C, Passer BJ, Shalak V, etal. Translationally controlled tumor protein acts as a guanine nucleotide dissociation inhibitor on the translation elongation factor eEF1A. Proc Natl Acad Sci U S A. 2003;100(24):13892-13897.
10. Amzallag N, Passer BJ, Allanic D, etal. TSAP6 facilitates the secretion of translationally controlled tumor protein/histamine-releasing factor via a nonclassical pathway. J Biol Chem. 2004;279(44):46104-46112.
11. Moldes M, Lasnier F, Gauthereau X, etal. Tumor necrosis factor-alpha-induced adipose-related protein (TIARP), a cell-surface that is highly induced by tumor necrosis factor-alpha and adipose conversion. J Biol Chem. 2001;276(36):33938-33946.
12. Korkmaz KS, Elbi C, Korkmaz CG, Loda M, Hager GL, Saatcioglu F. Molecular cloning and characterization of STAMP1, a highly prostate-specific six transmembrane protein that is overexpressed in prostate cancer. J Biol Chem. 2002;277(39):36689-36696.
13. Schroeder JT, Lichtenstein LM, MacDonald SM. An immunoglobulin E-dependent recombinant histamine releasing factor induces IL-4 secretion from human basophils. J Exp Med. 1996;183(3):1265-1270.
14. Schroeder JT, Lichtenstein LM, MacDonald SM. Recombinant histamine-releasing factor enhances IgE-dependent IL-4 and IL-13secretion by human basophils. J Immunol. 1997;159(1):447-452.
15. Bheekha-Escura R, Chance SR, Langdon JM, MacGlashan DW Jr, MacDonald SM. Pharmacologic regulation of histamine release by the human recombinant histamine-releasing factor. J Allergy Clin Immunol. 1999;103(5 Pt 1):937-943.
16. Wantke F, MacGlashan DW Jr, Langdon JM, MacDonald SM. The human recombinant histamine releasing factor: functional evidence that it does not bind to the IgE molecule. J Allergy Clin Immunol. 1999;103(4):642-648.
17. Bheekha-Escura R, MacGlashan DW Jr, Langdon JM, MacDonald SM. Human recombinant histamine-releasing factor activates human eosinophils and the eosinophilic cell line, AML14-13D10. Blood. 2000;96(6): 2191-2198.
18. Kashiwakura J, Ando T, Matsumoto K, etal. Proinflammatory role of histamine-releasing factor in mouse models of asthma and allergy. J Clin Invest. 2012;122(1):218-228.
19. Vonakis BM, Sora R, Langdon JM, Casolaro V, MacDonald SM. Inhibition of cytokine gene transcription by the human recombinant histamine-releasing factor in human T lymphocytes. J Immunol. 2003;171(7):3742-3750.
20. Kang HS, Lee MJ, Song H, etal. Molecular identification of IgE-dependent histamine-releasing factor as a B cell growth factor. J Immunol. 2001;166(11):6545-6554.
21. Yoneda K, Rokutan K, Nakamura Y, Yanagawa H, Kondo-Teshima S, Sone S. Stimulation of human bronchial epithelial cells by IgE-histamine-releasing factor. Am J Physiol Lung Cell Mol Physiol. 2004; 286(1):L174-L181.
22. Xu A, Bellamy AR, Taylor JA. Expression of translationally controlled tumour protein is regulated by calcium at both the transcriptional and post-transcriptional level. Biochem J. 1999;342 Pt 3:683-689.
23. Gachet Y, Tournier S, Lee M, Lazaris-Karatzas A, Poulton T, Bommer UA. The growth-related, translationally controlled protein P23 has properties of a tubulin binding protein and associates transiently with microtubules during the cell cycle. J Cell Sci. 1999;112(Pt 8): 1257-1271.
24. 2-dependent translocation of TCTP into the nucleus enables its interaction with VDR in human keratinocytes: TCTP as a further module in calcitriol signalling. J Steroid Biochem Mol Biol. 2010;118(1-2):29-40.
25. Fenner BJ, Scannell M, Prehn JH. Expanding the substantial interactome of NEMO using protein microarrays. PLoS One. 2010; 5(1):e8799.
26. Zhang D, Li F, Weidner D, Mnjoyan ZH, Fujise K. Physical and functional interaction between myeloid cell leukemia 1 protein (MCL1) and Fortilin. The potential role of MCL1 as a fortilin chaperone. J Biol Chem. 2002;277(40):37430-37438.
27. Yang Y, Yang F, Xiong Z, etal. An N-terminal region of translationally controlled tumor protein is required for its antiapoptotic activity. Oncogene. 2005;24(30):4778-4788.
28. Arcuri F, Papa S, Carducci A, etal. Translationally controlled tumor protein (TCTP) in the human prostate and prostate cancer cells: expression, distribution, and calcium binding activity. Prostate. 2004;60(2): 130-140.
29. Vercoutter-Edouart AS, Czeszak X, Crépin M, etal. Proteomic detection of changes in protein synthesis induced by fibroblast growth factor-2in MCF-7 human breast cancer cells. Exp Cell Res. 2001;262(1):59-68.
30. Chung S, Kim M, Choi W, Chung J, Lee K. Expression of translationally controlled tumor protein mRNA in human colon cancer. Cancer Lett. 2000;156(2):185-190.
31. Tuynder M, Fiucci G, Prieur S, etal. Translationally controlled tumor protein is a target of tumor reversion. Proc Natl Acad Sci U S A. 2004;101(43):15364-15369.
32. Li F, Zhang D, Fujise K. Characterization of fortilin, a novel antiapoptotic protein. J Biol Chem. 2001;276(50):47542-47549.
33. Susini L, Besse S, Duflaut D, etal. TCTP protects from apoptotic cell death by antagonizing bax function. Cell Death Differ. 2008;15(8): 1211-1220.
34. Rho SB, Lee JH, Park MS, etal. Anti-apoptotic protein TCTP controls the stability of the tumor suppressor p53. FEBS Lett. 2011;585(1):29-35.
35. Amson R, Pece S, Lespagnol A, etal. Reciprocal repression between P53 and TCTP. Nat Med. 2011;18(1):91-99.
36. Chen SH, Wu PS, Chou CH, etal. A knockout mouse approach reveals that TCTP functions as an essential factor for cell proliferation and survival in a tissue-or cell type-specific manner. Mol Biol Cell. 2007;18(7): 2525-2533.
37. Yueh-Chiao Y, Xie L, Langdon JM, etal. The effects of overespression of histamine releasing factor (HRF) in a transgenic mouse model. PloS ONE. 2010;5(6):e11077.
38. Schroeder JT. Basophils: Beyond effector cells of allergic inflammation. Adv Immunol. 2009;101:123-161.
39. Seder RA, Paul WE, Dvorak AM, etal. Mouse splenic and bone marrow cell populations that express high-affinity Fc epsilon receptors and produce interleukin 4 are highly enriched in basophils. Proc Natl Acad Sci U S A. 1991;88(77):2835-2839.
40. Min B, Paul W. Basophils and type 2 immunity. Curr Opin Hematol. 2008;15(1):59-63.
41. Obata K, Mukai K, Tsujimura Y, etal. Basophils are essential initiators of a novel type of chronic allergic inflammation. Blood. 2007;110(3):913-920.
42. Jacobsen EA, Ochkur SI, Pero RS, etal. Allergic pulmonary inflammation in mice is dependent on eosinophil-induced recruitment of effector T cells. J Exp Med. 2008;205(3):699-710.
43. Lee JJ, Dimina D, Macias MP, etal. Defining a link with asthma in mice congenitally deficient in eosinophils. Science. 2004;305(5691):1773-1776.
44. Mayr SI, Zuberi RI, Zhang M, etal. IgE-dependent mast cell activation potentiates airway responses in murine asthma models. J Immunol. 2002;169(4):2061-2068.
45. 2O sensitivity. Clin Exp Allergy. 1991;21(1): 133-138.
46. MacDonald SM, Schleimer RP, Kagey-Sobotka A, Gillis S, Lichtenstein LM. Recombinant IL-3induces histamine release from human basophils. J Immunol. 1989;142(10):3527-3532.
47. Kepley CL, Youssef L, Andrews RP, Wilson BS, Oliver JM. Syk deficiency in nonreleaser basophils. J Allergy Clin Immunol. 1999;104(2 Pt 1):279-284.
48. Lavens-Phillips SE, MacGlashan DW Jr. The tyrosine kinases p563/56lyn and p72syk are differentially expressed at the protein level but not at the messenger RNA level in nonreleasing human basophils. Am J Respir Cell Mol Biol. 2000;23(4):566-571.
49. Vilariño N, Miura K, MacGlashan DW Jr. Acute IL-3 priming up-regulates the stimulus-induced Raf-1-Mek-Erk cascade independently of IL-3-induced activation of Erk. J Immunol. 2005;175(5): 3006-3014.
50. Vonakis BM, Gibbons S Jr, Sora R, Langdon JM, MacDonald SM. Src homology 2 domain-containing inositol 5' phosphatase is negatively associated with histamine release to human recombinant histamine releasing factor in human basophils. J Allergy Clin Immunol. 2001;108(5):822-831.
51. Vonakis BM, Vasagar K, Gibbons SP Jr, etal. Basophil FcepsilonRI histamine release parallels expression of Src-homology 2-containing inositol phosphatases in chronic idiopathic urticaria. J Allergy Clin Immunol. 2007;119(2):441-448.
52. Krystal G. Lipid phosphatases in the immune system. Immunology. 2000;12(4):397-403.
53. Huber M, Helgason CD, Damen JE, etal. The src homology 2 containing inositol phosphatase (SHIP) is the gatekeeper of mast cell degranulation. Proc Natl Acad Sci U S A. 1998;95(19):11330-11335.
54. Rohrschneider LR, Fuller JF, Wolf I, Liu Y, Lucas DM. Structure, function and biology of SHIP proteins. Genes Dev. 2000;14(5):505-520.
55. Scharenberg AM, Kinet J-P. PtdIns-3,4,5-P3: a regulatory nexus between tyrosine kinases and sustained calcium signals. Cell. 1998;94(1):5-8.
56. Lioubin MN, Algate PA, Tsai S, Carlberg K, Aebersold A, Rohrschneider LR. p150Ship, a signal transduction molecule with inositol polyphosphate-5-phosphatase activity. Genes Dev. 1996,10(9): 1084-1095.
57. Ruschmann J, Antignano F, Lam V, etal. The role of SHIP in the development and activation of mouse mucosal and connective tissue mast cells. J Immunol. 2012;188(8):3839-3850.
58. Brauweiler AM, Tamir I, Cambier JC. Bilevel control of B-cell activation by the inositol 5-phosphatase SHIP. Immunol Rev. 2000;176:69-74.
59. 4 secretion following stimulation of human basophils with anti-IgE antibody. J Immunol. 2001;167(12): 7027-7037.
60. Vonakis BM, MacGlashan Jr DW, Vilariño N, Langdon JM, Scott RS, MacDonald SM. Distinct characteristics of signal transduction events by histamine releasing factor/translationally controlled tumor protein (HRF/TCTP)-induced priming and activation of human basophils. Blood. 2008;111(4):1789-1796.
61. Vilariño N, MacGlashan Jr D. Transient transfection of human peripheral blood basophils. J Immunol Meth. 2005;296(1-2):11-18.
62. Didichenko SA, Spiegl N, Brunner T, Dahinden CA. IL-3induces a Pim1-dependent antiapototic pathway in primary human basophils. Blood. 2008;112(10):3949-3958.
63. Langdon JM, Schroeder JT, Vonakis BM, Bieneman AP, Chichester K, MacDonald SM. Histamine-releasing factor/translationally controlled tumor protein (HRF/TCTP)-induced histamine release is enhanced with SHIP-1 knockdown in cultured human mast cell and basophil models. J Leukoc Biol. 2008;84(4):1151-1158.
64. Dombrowicz D, Flamand V, Brigman KK, Koller BH, Kinet JP. Abolition of anaphylaxis by targeted disruption of the high affinity immunoglobulin E receptor alpha chain gene. Cell. 1993;75(5):969-976.
65. Oettgen HC, Martin TR, Wynshaw-Boris A, Deng C, Drazen JM, Leder P. Active anaphylaxis in IgE-deficient mice. Nature. 1994; 370(6488):367-370.
66. Miura K, Schroeder JT, Hubbard WC, MacGlashan DW Jr. Extracellular signal-regulated kinases regulate leukotriene C4generation, but not histamine release or IL-4 production from human basophils. J Immunol. 1999;162(7):4198-4206.
67. MacDonald SM, Kagey-Sobotka A, Proud D, Naclerio RM, Lichtenstein LM. Histamine-releasing factor: release mechanism and responding population. J Allergy Clin Immunol. 1987;79:248.
68. MacDonald SM. Histamine releasing factors and IgE heterogeneity. In: Middleton E, Reed CE, Ellis EF, Adkinson NF, Yunginger JW, Buss WW, editors. Allergy: Principles and Practice. 4th Edition, 1993:1-11.
69. Alam R, Rozniecki J, Salmaj K. A mononuclear cell derived histamine releasing factor (HRF) in asthmatic patients. Histamine release from basophils in vitro. Ann Allergy. 1984;53(1):66-69.
70. Alam R, Rozniecki J. A mononuclear cell-derived histamine releasing factor in asthmatic patients. II. Activity in vivo. Allergy. 1985;40(2):124-129.
71. Alam R, Kuna P, Rozniecki J, Kuzminska B. The magnitude of the spontaneous production of histamine-releasing factor (HRF) by lymphocytes in vitro correlates with the state of bronchial hyperreactivity in patients with asthma. J Allergy Clin Immunol. 1987;79(1):103-108.
72. Sampson HA, Broadbent KR, Bernhisel-Broadbent J. Spontaneous release of histamine from basophils and histamine-releasing factor in patients with atopic dermatitis and food hypersensitivity. N Engl J Med. 1989;321(4):228-232.
73. Kuna P, Alam R, Kuzminska B, Rozniecki J. The effect of preseasonal immunotherapy on the production of histamine-releasing factor (HRF) by mononuclear cells from patients with seasonal asthma: results of a double-blind, placebo-controlled, randomized study. J Allergy Clin Immunol. 1989;83(4):816-882.
74. Brunet C, Bédard PM, Lavoie A, Jobin M, Hébert J. Allergic rhinitis to ragweed pollen. II. Modulation of histamine-releasing factor production by specific immunotherapy. J Allergy Clin Immunol. 1992;89(1 Pt 1): 87-94.
75. MacDonald SM. Histamine-releasing factors. Curr Opi Immunol. 1996;8(6):778-783.
76. Langdon J, Anders K, Lichtenstein LM, MacDonald SM. Atopics translate mRNA for the IgE-dependent histamine releasing factor (HRF) more effectively than normal. J Allergy Clin Immunol. 1995;95:336 (Abstract).
77. Ando T, Kashiwakura J, Kawakami Y, Kawakami T. Histamine releasing factor (HRF) in asthma and atopic dermatitis. J Immunol. 2012; 188:177.16 (Abstract).
78. Ong CJ, Ming-Lum A, Nodwell M, etal. Small-molecule agonists of SHIP1 inhibit the phosphoinositide 3-kinase pathway in hematopoietic cells. Blood. 2007;110(6):1942-1949.
79. Tam P, Mackenzie LF, Toews J, etal. Absorption, pharmacokinetics, metabolism, distribution and tolerability of AQX-1125, a SHIP1 activator clinical development candidate, in healthy humans volunteers: comparison with dogs and rats. ATS Abstract, May 2012.
80. MacDonald SM. Histamine releasing factor/translational controlled tumor protein: history, functions and clinical implications. Open Allergy Journal. 2012;5:12-18.